Comments on: Life sciences briefing: Friday, Aug. 24, 2007

By: Precision Thera merger with “blank check” Oracle Healthcare collapses » VentureBeat

Wed, 05 Mar 2008 16:35:43 +0000

[...] saga of Precision Therapeutics, a Pittsburgh biotech developing what struck me last August as a particularly crude type of cancer-chemotherapy diagnostic, continues apace. In a tersely worded press release, the special-purpose acquisition company Oracle [...]

By: Life sciences briefing: Wednesday, March 5, 2008 » VentureBeat

Life sciences briefing: Wednesday, March 5, 2008 » VentureBeat — Wed, 05 Mar 2008 15:02:23 +0000

By: Life sciences briefing: Friday, Feb. 22, 2008 » VentureBeat

Life sciences briefing: Friday, Feb. 22, 2008 » VentureBeat — Sat, 23 Feb 2008 23:21:06 +0000

[...] now isn’t remotely clear. I’m certainly tempted to think that Precision is turning out less of a bargain Oracle thought, but at this point, it’s impossible to know for [...]

By: Venture Beat: Brace yourselves for the SPAC attack at Conceptualist.com, By Sahar Sarid

Tue, 12 Feb 2008 16:15:07 +0000

[...] the last. In December, a SPAC took out Precision Therapeutics, a maker of cancer diagnostics that looked shaky to me when it first filed for an IPO. Then just last week, a different SPAC bought up specialty pharma [...]

By: VentureBeat » Precision Thera drops IPO, goes public via reverse merger

VentureBeat » Precision Thera drops IPO, goes public via reverse merger — Tue, 04 Dec 2007 18:35:30 +0000

[...] was pretty hard on Precision when it filed its IPO, since its cancer diagnostic test not only struck me as fairly crude and simplistic, it also lacks [...]

By: VentureBeat » Life sciences briefing: Monday, Oct. 8, 2007

VentureBeat » Life sciences briefing: Monday, Oct. 8, 2007 — Tue, 09 Oct 2007 09:12:44 +0000

[...] reportedly postponed an IPO that had been scheduled for that week. (See our previous coverage here, here and [...]

By: VentureBeat » Life sciences briefing: Friday, Sept. 21, 2007

VentureBeat » Life sciences briefing: Friday, Sept. 21, 2007 — Mon, 01 Oct 2007 20:26:16 +0000

[...] Zars Pharma delays IPO — Salt Lake City’s Zars Pharma, a developer of topical drugs, postponed its IPO until next week. Zars priced its IPO at $14 to $16 a share in August, and was slated to hit the market this week. See our previous coverage here and in the third item here. [...]